The Gemini Trials: NCT04410978 & NCT04410991
Patients with relapsing forms of multiple sclerosis are encouraged to take a 2-minute pre-screener to see if they may qualify for the Gemini Trials.
- Relapsing Multiple Sclerosis (RMS)
- ages 18 to 55 years
The Gemini 1 and Gemini 2 Trials are Phase III clinical trials designed to assess the efficacy and safety of the trial drug against an existing treatment medication, teriflunomide. The efficacy and safety of the trial drug is measured by comparing the number of relapses per year confirmed by an independent group of MS specialists in patients diagnosed with relapsing forms of multiple sclerosis (RMS). Patients will be randomly selected to receive the trial drug or the existing treatment medication.
Additional goals of the trials will be to test the effect of the trial drug on disability progression, magnetic resonance imaging (MRI) lesions, the ability to learn and process information, and quality of life, as well as the safety and tolerability of the trial medication.
Those who qualify to participate in clinical trials may receive medical care and medication at no cost to the patient. People who participate in clinical trials aid others with the same condition by helping the scientific community find new treatment options for diseases such as multiple sclerosis.